Hepion chair granted 1.35M options at $0.08

Hepion Pharmaceuticals, Inc. (HEPA) reported that Executive Chairman Vincent S. LoPriore received a grant of stock options on 2026-08-19.

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. (HEPA) reported that Executive Chairman Vincent S. LoPriore received a grant of stock options on 2026-08-19. The award covers 1,345,500 options to acquire common stock at an exercise price of $0.08 per share, expiring on 2036-08-19. According to the footnote, 336,375 options vest upon grant and the remaining options vest in equal monthly installments over six months from the grant date. Following this grant, LoPriore holds 1,345,500 stock options directly.

Insider Trade Summary

Grant/Award: 1,345,500 shares

Grant/Award 1 txn

Insider LoPriore Vincent S

Role Executive Chairman

Type	Security	Shares	Price	Value
Grant/Award	Stock Options F1	1,345,500	$0.00	$0.00

Holdings After Transaction: Stock Options — 1,345,500 contracts (Direct)

Footnotes (1)

1. F1. 336,375 options vest upon grant and the remaining amount vests in equal amounts monthly over 6 months from date of grant.

Key Figures

Stock options granted: 1,345,500 options Exercise price: $0.08 per share Immediate vesting portion: 336,375 options +3 more

6 metrics

Stock options granted 1,345,500 options Grant to Executive Chairman Vincent S. LoPriore on 2026-08-19

Exercise price $0.08 per share Conversion or exercise price for granted stock options

Immediate vesting portion 336,375 options Options that vest upon grant per footnote F1

Expiration date 2036-08-19 Expiration date of the granted stock options

Underlying shares 1,345,500 shares Common stock underlying the granted options

Options held after transaction 1,345,500 options Total derivative holdings reported following the grant

Key Terms

Stock Options, exercise price, expiration date, vesting

4 terms

Stock Options financial

"The security title is listed as "Stock Options" for this grant"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"The filing shows a conversion or exercise price of 0.0800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"An expiration date of 2036-08-19 is provided for the options"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"Footnote F1 explains that some options vest upon grant and others monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did HEPA disclose for Vincent S. LoPriore?

Hepion Pharmaceuticals (HEPA) disclosed that Executive Chairman Vincent S. LoPriore received a grant of 1,345,500 stock options on 2026-08-19 as a derivative security award, rather than buying or selling shares on the open market.

What is the exercise price and term of the new HEPA stock options?

The granted stock options have an exercise price of $0.08 per share and an expiration date of 2036-08-19, giving Vincent S. LoPriore the right to acquire Hepion common stock at that price until that date.

How do the new HEPA options granted to LoPriore vest?

The filing states that 336,375 options vest upon grant, and the remaining options vest in equal amounts monthly over six months from the 2026-08-19 grant date.

How many HEPA options does Vincent S. LoPriore hold after this transaction?

After the reported grant, Vincent S. LoPriore holds 1,345,500 stock options directly, as shown in the post-transaction holdings figure in the Form 4.

Was the HEPA option grant to LoPriore made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not affirmed (false), and there is no footnote indicating the grant was made pursuant to a Rule 10b5-1 or other pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 04:35 PM EDT Accepted by SEC EDGAR 08/21/2026 - 04:34 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LoPriore Vincent S

(Last) (First) (Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK, NEW JERSEY 07701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$0.08	08/19/2026		A		1,345,500		08/19/2026(1)	08/19/2036	Common Stock	1,345,500	$0	1,345,500	D

Explanation of Responses:

1. 336,375 options vest upon grant and the remaining amount vests in equal amounts monthly over 6 months from date of grant.

	/s/ Vincent LoPriore	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)